394 related articles for article (PubMed ID: 27071790)
1. mTOR, a Potential Target to Treat Autism Spectrum Disorder.
Sato A
CNS Neurol Disord Drug Targets; 2016; 15(5):533-43. PubMed ID: 27071790
[TBL] [Abstract][Full Text] [Related]
2. Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder.
Tilot AK; Frazier TW; Eng C
Neurotherapeutics; 2015 Jul; 12(3):609-19. PubMed ID: 25916396
[TBL] [Abstract][Full Text] [Related]
3. mTOR Signaling Disruption and Its Association with the Development of Autism Spectrum Disorder.
Thomas SD; Jha NK; Ojha S; Sadek B
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838876
[TBL] [Abstract][Full Text] [Related]
4. [Abnormal mTOR Signaling Pathway Activity in Autism Spectrum Disorders: Prospects of Mechanism-Based Therapy].
Trifonova EA; Kotliarova AA; Kochetov AV
Mol Biol (Mosk); 2023; 57(2):243-253. PubMed ID: 37000653
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Akt-mTOR pathway rescued the social behavior in Cntnap2-deficient mice.
Xing X; Zhang J; Wu K; Cao B; Li X; Jiang F; Hu Z; Xia K; Li JD
Sci Rep; 2019 Feb; 9(1):3041. PubMed ID: 30816216
[TBL] [Abstract][Full Text] [Related]
6. Do Autism Spectrum and Autoimmune Disorders Share Predisposition Gene Signature Due to mTOR Signaling Pathway Controlling Expression?
Trifonova EA; Klimenko AI; Mustafin ZS; Lashin SA; Kochetov AV
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065644
[TBL] [Abstract][Full Text] [Related]
7. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
8. Abnormal mTOR Activity in Pediatric Autoimmune Neuropsychiatric and MIA-Associated Autism Spectrum Disorders.
Trifonova EA; Mustafin ZS; Lashin SA; Kochetov AV
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055151
[TBL] [Abstract][Full Text] [Related]
9. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Davis PE; Peters JM; Krueger DA; Sahin M
Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
[TBL] [Abstract][Full Text] [Related]
10. Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder?
Magdalon J; Sánchez-Sánchez SM; Griesi-Oliveira K; Sertié AL
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335463
[TBL] [Abstract][Full Text] [Related]
11. mTOR-related synaptic pathology causes autism spectrum disorder-associated functional hyperconnectivity.
Pagani M; Barsotti N; Bertero A; Trakoshis S; Ulysse L; Locarno A; Miseviciute I; De Felice A; Canella C; Supekar K; Galbusera A; Menon V; Tonini R; Deco G; Lombardo MV; Pasqualetti M; Gozzi A
Nat Commun; 2021 Oct; 12(1):6084. PubMed ID: 34667149
[TBL] [Abstract][Full Text] [Related]
12. Abnormal mTOR Activation in Autism.
Winden KD; Ebrahimi-Fakhari D; Sahin M
Annu Rev Neurosci; 2018 Jul; 41():1-23. PubMed ID: 29490194
[TBL] [Abstract][Full Text] [Related]
13. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
[TBL] [Abstract][Full Text] [Related]
14. Protein Phosphorylation Signaling Cascades in Autism: The Role of mTOR Pathway.
Boksha IS; Prokhorova TA; Tereshkina EB; Savushkina OK; Burbaeva GS
Biochemistry (Mosc); 2021 May; 86(5):577-596. PubMed ID: 33993859
[TBL] [Abstract][Full Text] [Related]
15. The mTOR Signaling Pathway Activity and Vitamin D Availability Control the Expression of Most Autism Predisposition Genes.
Trifonova EA; Klimenko AI; Mustafin ZS; Lashin SA; Kochetov AV
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847491
[TBL] [Abstract][Full Text] [Related]
16. Genetic and Environmental Contributions to Autism Spectrum Disorder Through Mechanistic Target of Rapamycin.
Sato A; Ikeda K
Biol Psychiatry Glob Open Sci; 2022 Apr; 2(2):95-105. PubMed ID: 36325164
[TBL] [Abstract][Full Text] [Related]
17. Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTOR.
Oguro-Ando A; Rosensweig C; Herman E; Nishimura Y; Werling D; Bill BR; Berg JM; Gao F; Coppola G; Abrahams BS; Geschwind DH
Mol Psychiatry; 2015 Sep; 20(9):1069-78. PubMed ID: 25311365
[TBL] [Abstract][Full Text] [Related]
18. [Research advances in the role of mTOR signaling pathway in autism spectrum disorder].
Sheng GX; Jiang KW
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jul; 21(7):718-723. PubMed ID: 31315775
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders.
Yui K; Sato A; Imataka G
Mini Rev Med Chem; 2015; 15(5):373-89. PubMed ID: 25910652
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of mTOR signaling mediates common neurite and migration defects in both idiopathic and 16p11.2 deletion autism neural precursor cells.
Prem S; Dev B; Peng C; Mehta M; Alibutud R; Connacher RJ; St Thomas M; Zhou X; Matteson P; Xing J; Millonig JH; DiCicco-Bloom E
Elife; 2024 Mar; 13():. PubMed ID: 38525876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]